EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Leptin and leptin receptor in patients with chronic hepatitis C Effect of interferon/ribavirin combination therapy


, : Leptin and leptin receptor in patients with chronic hepatitis C Effect of interferon/ribavirin combination therapy. Gastroenterology 122(4 Suppl 1): A 644, April



Accession: 035216334

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Asahina, Y.; Izumi, N.; Ueda, K.; Inoue, K.; Nishimura, Y.; Tsuchiya, K.; Hamano, K.; Itakura, J.; Noguchi, O.; Uchihara, M.; Miyake, S.; Enomoto, N., 2003: Mutagenic effect of ribavirin in ns5a and ns5b regions and response to interferon/ribavirin combination therapy in patients with chronic hepatitis c. BACKGROUND/AIM: Mechanisms involving antiviral effect of ribavirin against HCV have not been fully elucidated in vivo. To determine the mutagenic effect of ribavirin on clinical response to IFN/ribavirin combination therapy, NS5A and NS5B regions...

Stauber, R.E.; Hofer, H.; Hackl, F.; Schütze, K.; Datz, C.; Hegenbarth, K.; Jessner, W.; Steindl-Munda, P.; Peter, F., 2004: Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. There is currently no accepted therapeutic regimen for patients with chronic hepatitis C who failed to respond to standard combination treatment with interferon-alpha plus ribavirin. We investigated triple combination treatment with induction dosi...

Ferenci, P.; Stauber, R.; Hackl, F.; Schuetze, K.; Bauer, B.; Datz, C., 2000: Treatment with amantadine + ribavirin + interferon in patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy. Gastroenterology 118(4 Suppl 2 Part 2): AASLD A143, April

Kaito, M.; Iwasa, M.; Fujita, N.; Kobayashi, Y.; Kojima, Y.; Ikoma, J.; Imoto, I.; Adachi, Y.; Hamano, H.; Yamauchi, K., 2007: Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. Objectives: Lactoferrin has been reported to inhibit hepatitis C virus (HCV) infection in cultured human hepatocytes and HCV viremia in patients with chronic hepatitis C (CHC). The aim of this study was to evaluate the effect of combined triple th...

Jacobson, I.; Russo, M.W.; Brown, R.S.; Lebovics, E.; Min, A.; Esposito, S.; Tobias, H.; Klion, F.; Rovner, D.; Brass, C.; N.P.g Intron Study Group, 2002: Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers. Hepatology 36(4 Part 2): 358A, October

Chemello, L.; Cavalletto, L.; Bernardinello, E.; Guido, M.; Pontisso, P.; Alberti, A., 1995: The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. Background. Chronic hepatitis C may lead to cirrhosis and hepatocellular carcinoma in a subset of patients. Because response rates with interferon alfa therapy are unsatisfactory, new therapies are needed. Methods: We conducted a three-arm, random...

Hoofnagle, J.H.; Ghany, M.G.; Kleiner, D.E.; Doo, E.; Heller, T.; Promrat, K.; Ong, J.; Khokhar, F.; Soza, A.; Herion, D.; Park, Y.; Everhart, J.E.; Liang, T.Jake., 2003: Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. To assess the efficacy and safety of maintenance therapy with ribavirin alone in chronic hepatitis C, 108 patients were treated with the combination of interferon alfa and ribavirin for 24 weeks; those who failed to have a virologic response were...

Jacobson, I.M.; Ahmed, F.; Russo, M.W.; Brown, R.S.J.; Lebovics, E.; Min, A.; Esposito, S.; Brau, N.; Tobias, H.; Klion, F.; Bini, E.; Brodsky, N., 2003: Pegylated interferon alfa 2b plus ribavirin in patients with chronic hepatitis c a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers final results. Background: Pegylated interferon (PEG IFN) has proven superior to standard interferon (IFN) as monotherapy for chronic hepatitis C and, more recently, in combination with ribavirin (RBV) in treatment naive patients. Aim: To compare the efficacy of...

Nagayama, R.; Tanaka, A.; Ankoh, H.; Narita, T.; Izumi, M.; Miyake, K.; Takikawa, H., 2005: Efficacy of ribavirin monotherapy following combination therapy with interferon alfa-2b and ribavirin for patients with chronic hepatitis C. Reappearance of HCV-RNA followed by exacerbation of biochemical parameters after combination therapy consisting of interferon and ribavirin is an obstacle to achieve sustained response and improve long-term prognosis. We hypothesed that ribavirin...

Arase, Y.; Ikeda, K.; Suzuki, F.; Suzuki, Y.; Saitoh, S.; Kobayashi, M.; Akuta, N.; Someya, T.; Hosaka, T.; Sezaki, H.; Kobayashi, M.; Kumada, H., 2004: Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C. Background. Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin. Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy. In this clinical retrospective...